Domestic innovative drugs "blockbusters" are emerging one after another, and the commercialization process is speeding up comprehensively.

Chinese innovative pharmaceutical companies have recently handed in their "report cards" for 2025 one after another. The Securities Times reporter noticed that a group of domestically produced innovative drugs with strong clinical value, known as "blockbuster drugs," have emerged one after another, not only becoming the core pillar of enterprise profitability, but also marking a breakthrough from research and development-driven innovation drugs to commercialization. The conditions for achieving a blockbuster innovative drug are extremely harsh. The product itself must have strong competitiveness, and it must also be in a vast market field or target an unmet clinical need in the market. Now, with a group of domestically produced blockbuster innovative drugs already "out there," how to break through the "patent cliff" constraints and continue to create the next batch of blockbuster drugs will become a new proposition for the industry to move towards high-quality development.